



ZIYUANYUAN HOLDINGS GROUP LIMITED
紫元元控股集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)
Stock code 股份代號 : 8223

First
Quarterly
Report
第一季度報告
2022



CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors (the "Directors") of Ziyuanyuan Holdings Group Limited (the "Company") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading.

香港聯合交易所有限公司（「聯交所」）GEM的特色

GEM乃為較於聯交所上市的其他公司可能帶有更高投資風險的中小型公司而設的市場。有意投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。

由於GEM上市公司普遍為中小型公司，於GEM買賣的證券可能會較於聯交所主板買賣的證券承受較大的市場波動風險，同時無法保證於GEM買賣的證券會有高流通量的市場。

香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本報告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。

本報告乃遵照GEM證券上市規則的規定而提供有關紫元元控股集團有限公司（「本公司」）的資料，本公司之董事（「董事」）願就本報告共同及個別地承擔全部責任。董事在作出一切合理查詢後，確認就彼等所知及所信，本報告所載資料在各重要方面均屬準確完整，並無誤導或欺詐成份，亦無遺漏任何其他事項，致使當中任何陳述或本報告產生誤導。

CONTENTS

目錄

| | | Page 頁次 |
|--|------------------------|------------|
| CONTENTS | 目錄 | 2 |
| UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME | 未經審核簡明綜合損益及 其他全面收益表 | 3 |
| UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY | 未經審核簡明綜合權益變動表 | 4 |
| NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | 未經審核簡明綜合財務報表附註 | 6 |
| MANAGEMENT DISCUSSION AND ANALYSIS | 管理層討論及分析 | 13 |
| OTHER INFORMATION | 其他資料 | 21 |

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

未經審核簡明綜合損益及其他全面收益表

For the three months ended 31 March 2022
截至二零二二年三月三十一日止三個月

The board of Directors (the “**Board**”) hereby announces the unaudited condensed consolidated financial results of the Company and its subsidiaries (the “**Group**”) for the three months ended 31 March 2022, together with the comparative unaudited figures for the corresponding period in 2021, as follows:

董事會(「**董事會**」)謹此公佈本公司及其附屬公司(「**本集團**」)截至二零二二年三月三十一日止三個月之未經審核簡明綜合財務業績，連同二零二一年同期之比較未經審核數字如下：

| | | Three months ended 31 March 截至三月三十一日止三個月 | |
|---|---|--|--|
| | | 2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核) | 2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核) |
| | | Notes 附註 | |
| Revenue | 收益 | | |
| Finance leasing income | 融資租賃收入 | | 12,863 |
| Interest income from loan receivables | 應收貸款利息收入 | | 290 |
| Income from postpartum care services | 月子服務收入 | | 9,400 |
| Income from trading of medical equipment and consumables | 醫療器械及耗材貿易收入 | | – |
| | | 8,111 | |
| Total revenue | 總收益 | 31,753 | 22,553 |
| Cost of sales | 銷售成本 | (6,611) | – |
| Bank interest income | 銀行利息收入 | 34 | 96 |
| Other gains and losses | 其他收益及虧損 | 1,209 | 1,338 |
| Staff costs | 員工成本 | (10,136) | (7,597) |
| Reversal of impairment losses/ (impairment losses) under expected credit loss (“ ECL ”) model, net | 預期信用損失(「 預期信用損失 」)模式項下之減值虧損撥回/(減值虧損)淨額 | 1,100 | (254) |
| Other operating expenses | 其他經營開支 | (12,031) | (10,503) |
| Finance costs | 融資成本 | (3,186) | (2,041) |
| Profit before income tax | 除所得稅前溢利 | 2,132 | 3,592 |
| Income tax expenses | 所得稅開支 | (237) | (521) |
| Profit and total comprehensive income for the period | 期內溢利及全面收入總額 | 1,895 | 3,071 |
| Profit and total comprehensive income for the period attributable to: | 期內溢利及全面收入總額應佔： | | |
| Owners of the Company | 本公司擁有人 | 2,155 | 3,011 |
| Non-controlling interests | 非控股權益 | (260) | 60 |
| | | 1,895 | 3,071 |
| Earnings per share for profit attributable to owners of the Company during the period – Basic and diluted (RMB cents) | 本公司擁有人期內應佔每股盈利 — 基本及攤薄(人民幣分) | 0.54 | 0.75 |

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

未經審核簡明綜合權益變動表

For the three months ended 31 March 2022

截至二零二二年三月三十一日止三個月

| | | Attributable to owners of the Company 本公司擁有人應佔 | | | | | Non- controlling interests 非控股權益 | Total 總計 | |
|---|----------------------------|---|--------------------------|---|-------------------------------|-----------------------------|---|------------------|----------------|
| | | Share capital 股本 | Share premium 股份溢價 | Capital and other reserves 其他儲備 資本及 其他儲備 | Statutory reserves 法定儲備 | Retained profits 保留溢利 | Total | | |
| | | RMB'000 人民幣千元 | RMB'000 人民幣千元 | RMB'000 人民幣千元 | RMB'000 人民幣千元 | RMB'000 人民幣千元 | RMB'000 人民幣千元 | RMB'000 人民幣千元 | |
| | | | (Note (i)) (附註(i)) | (Note (ii)) (附註(ii)) | (Note (iii)) (附註(iii)) | | | | |
| At 1 January 2022 (audited) | 於二零二二年 一月一日 (經審核) | 33,839 | 65,218 | 133,023 | 9,411 | 58,032 | 299,523 | 4,799 | 304,322 |
| Profit and total comprehensive income for the period | 期內溢利及全面 收入總額 | - | - | - | - | 2,155 | 2,155 | (260) | 1,895 |
| At 31 March 2022 (unaudited) | 於二零二二年 三月三十一日 (未經審核) | <u>33,839</u> | <u>65,218</u> | <u>133,023</u> | <u>9,411</u> | <u>60,187</u> | <u>301,678</u> | <u>4,539</u> | <u>306,217</u> |
| At 1 January 2021 (audited) | 於二零二一年 一月一日 (經審核) | 33,839 | 73,551 | 133,023 | 8,817 | 53,138 | 302,368 | 944 | 303,312 |
| Profit and total comprehensive income for the period | 期內溢利及全面 收入總額 | - | - | - | - | 3,011 | 3,011 | 60 | 3,071 |
| Acquisition of subsidiaries | 收購附屬公司 | - | - | - | - | - | - | 3,254 | 3,254 |
| At 31 March 2021 (unaudited) | 於二零二一年 三月三十一日 (未經審核) | <u>33,839</u> | <u>73,551</u> | <u>133,023</u> | <u>8,817</u> | <u>56,149</u> | <u>305,379</u> | <u>4,258</u> | <u>309,637</u> |

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

未經審核簡明綜合權益變動表

For the three months ended 31 March 2022
截至二零二二年三月三十一日止三個月

Notes:

- (i) Under the Companies Law (Revised) of the Cayman Islands, share premium is distributable to shareholders, subject to the condition that the Company cannot declare or pay a dividend, or make a distribution out of share premium if (i) it is, or would after the payment be, unable to pay its liabilities as they become due; or (ii) the realisable value of its assets would thereby be less than aggregate of its liabilities and its issued share capital account.
- (ii) Capital and other reserves represents (i) the reserve arising from the acquisition of 55% equity interest of Ziyuanyuan (Shenzhen) International Finance Leasing Company Limited (“**ZYY Finance Leasing**”), a subsidiary of the company, through acquisition of HK Lixin Trade Co., Limited (“**HK Lixin**”); (ii) the difference between the aggregate of the issued capital of HK Lixin and ZYY Finance Leasing directly attributable to Mr. Zhang Junshen and Mr. Zhang Junwei, the controlling individual shareholders of the Company (the “**Controlling Individual Shareholders**”) and the net assets value of HK Lixin upon insertion of the Company and Honor Global Holding Limited as part of the group reorganisation; (iii) the consideration paid on the acquisition of the remaining 45% equity interest of ZYY Finance Leasing by HK Lixin from the Controlling Individual Shareholders; and (iv) Hero Global Limited (“**Hero Global**”), an immediate holding company of the Company, waived an amount due from HK Lixin, a subsidiary of the Company, amounting to RMB68,000,000, which was accounted for as a deemed capital contribution from a shareholder.
- (iii) Pursuant to the articles of association of the subsidiaries established in the People’s Republic of China (the “**PRC**”), it is required to appropriate 10% or an amount to be determined by its directors of its profit after taxation in accordance with the relevant PRC regulations before any distribution of dividends to owners each year to the statutory reserve until the balance reaches 50% of its registered capital.

附註：

- (i) 根據開曼群島公司法（經修訂），股份溢價是可分配給股東，但前提是公司不可以宣告或分派股息，或者在以下情況下不能從股份溢價中進行分配：(i)分派股息後，公司無法償還到期的債務；或(ii)其資產的可變現價值將因此小於其負債和已發行股本賬戶的總和。
- (ii) 資本及其他儲備指(i)因通過收購香港立信貿易有限公司（「**香港立信**」）而收購本公司附屬公司紫元元（深圳）國際融資租賃有限公司（「**紫元元融資租賃**」）的55%股權而產生的儲備；(ii)本公司控股個人股東張俊深先生及張俊偉先生（「**控股個人股東**」）直接應佔香港立信及紫元元融資租賃的已發行股本總額與待加入本公司及榮耀全球控股有限公司作為集團重組一部分後的香港立信資產淨值之間的差額；(iii)香港立信向控股個人股東收購紫元元融資租賃餘下45%股權而支付的代價；及(iv)本公司直接控股公司Hero Global Limited（「**Hero Global**」）豁免應收本公司附屬公司香港立信的款項人民幣68,000,000元，其入賬列為視作股東出資。
- (iii) 根據於中華人民共和國（「**中國**」）成立的附屬公司的組織章程細則，每年向擁有人分派任何股息前，須按有關中國法規將10%或董事所釐定金額的除稅後溢利撥入法定儲備，直至其結餘達到註冊資本的50%。

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

未經審核簡明綜合財務報表附註

1. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards (“HKFRSs”) issued by the Hong Kong Institute of Certified Public Accountants (the “HKICPA”) as well as with the applicable disclosure requirements of Chapter 18 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited.

2. PRINCIPAL ACCOUNTING POLICIES

The unaudited condensed consolidated financial statements have been prepared under historical cost convention, except for certain financial instruments, which are stated at fair value.

The preparation of the unaudited consolidated financial results in conformity with HKFRSs requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. Except as described below, the accounting policies used in the preparation of these unaudited condensed consolidated financial statements for the three months ended 31 March 2022 are consistent with those followed in the preparation of the Group’s annual audited financial statements for the year ended 31 December 2021.

Application of new and amendments to HKFRSs

In the current period, the Group has applied the new and amendments to HKFRSs issued by the HKICPA which are effective for the annual period beginning on or after 1 January 2022 for the preparation of the Group’s unaudited condensed consolidated financial statements.

The application of new and amendments to HKFRSs in the current period has no material impact on the amounts reported and/or disclosures set out in these unaudited condensed consolidated financial statements.

1. 編製基準

未經審核簡明綜合財務報表乃按照香港會計師公會（「香港會計師公會」）頒佈的香港財務報告準則（「香港財務報告準則」）及香港聯合交易所有限公司GEM證券上市規則第十八章的適用披露規定編製。

2. 主要會計政策

未經審核簡明綜合財務報表乃按照歷史成本慣例編製，惟若干財務工具按公平價值計量。

編制符合香港財務報告準則之未經審核綜合財務業績須使用若干關鍵會計估計。其亦需要管理層於應用本集團之會計政策之過程中行使其判斷。除下文所述者外，編製該等截至二零二二年三月三十一日止三個月之未經審核簡明綜合財務報表時所用之會計政策與編製本集團截至二零二一年十二月三十一日止年度之經審核年度財務報表所依循者一致。

應用新訂香港財務報告準則及香港財務報告準則的修訂

於本期間，本集團應用由香港會計師公會頒佈的新訂香港財務報告準則及香港財務報告準則的修訂。就編製本集團之未經審核簡明綜合財務報表而言，該等準則及修訂乃就於二零二二年一月一日或之後開始的年度期間生效。

於本期間應用新訂香港財務報告準則及香港財務報告準則的修訂對該等未經審核簡明綜合財務報表所載的呈報金額及／或披露事項並無重大影響。

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

未經審核簡明綜合財務報表附註

3. REVENUE

Revenue for the period represents finance leasing income, interest income on loan receivables, income from postpartum care services and income from trading of medical equipment and consumables in the PRC. The amounts of each significant category of revenue recognised in revenue during the period are as follows:

3. 收益

期內收益指來自於中國之融資租賃收入、應收貸款利息收入、月子服務收入及醫療器械及耗材貿易收入。本期間在收益中確認的每個重大收入類別的金額如下：

| | | Three months ended 31 March | |
|--|-------------|--|-------------|
| | | 截至三月三十一日止三個月 | |
| | | 2022 | 2021 |
| | | 二零二二年 | 二零二一年 |
| | | RMB'000 | RMB'000 |
| | | 人民幣千元 | 人民幣千元 |
| | | (Unaudited) | (Unaudited) |
| | | (未經審核) | (未經審核) |
| Finance leasing income | 融資租賃收入 | 11,271 | 12,863 |
| Interest income from loan receivables | 應收貸款利息收入 | 502 | 290 |
| Income from postpartum care services | 月子服務收入 | 11,869 | 9,400 |
| Income from trading of medical equipment and consumables | 醫療器械及耗材貿易收入 | 8,111 | - |
| | | 31,753 | 22,553 |
| | | 31,753 | 22,553 |

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

未經審核簡明綜合財務報表附註

4. OTHER GAINS AND LOSSES

4. 其他收益及虧損

| | | Three months ended 31 March | |
|--|---------------------|--------------------------------|--------------|
| | | 截至三月三十一日止三個月 | |
| | | 2022 | 2021 |
| | | 二零二二年 | 二零二一年 |
| | | RMB'000 | RMB'000 |
| | | 人民幣千元 | 人民幣千元 |
| | | (Unaudited) | (Unaudited) |
| | | (未經審核) | (未經審核) |
| Fair value gain on financial assets at fair value through profit or loss | 公平價值計入損益之金融資產的公平價收益 | 1,020 | 556 |
| Government subsidies (Note) | 政府補貼 (附註) | 240 | 729 |
| Exchange (loss)/gain, net | 匯兌(虧損)/收益淨額 | (55) | 3 |
| Others | 其他 | 4 | 50 |
| | | <u>1,209</u> | <u>1,338</u> |

Note:

The PRC tax authority has announced that for the years ended 31 December 2021 and 31 December 2022, entities engaged in provision of service in four particular areas could have extra deduction on VAT.

附註:

中國稅務機關宣佈，截至二零二一年十二月三十一日及二零二二年十二月三十一日止年度，於四個特定領域從事提供服務之實體可額外扣除增值稅。

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

未經審核簡明綜合財務報表附註

5. (REVERSAL OF IMPAIRMENT LOSSES)/ IMPAIRMENT LOSSES UNDER ECL MODEL, NET

5. 預期信用損失模式項下之 (減值虧損撥回) / 減值虧損 淨額

| | | Three months ended 31 March | |
|--|-----------------------|--------------------------------|-------------|
| | | 截至三月三十一日止三個月 | |
| | | 2022 | 2021 |
| | | 二零二二年 | 二零二一年 |
| | | RMB'000 | RMB'000 |
| | | 人民幣千元 | 人民幣千元 |
| | | (Unaudited) | (Unaudited) |
| | | (未經審核) | (未經審核) |
| (Reversal of impairment losses)/ impairment losses recognised on: | (減值虧損撥回) / 減值虧損確認： | | |
| – finance lease receivables | – 融資租賃應收款項 | (1,097) | 296 |
| – loan receivables | – 應收貸款 | (3) | (42) |
| | | (1,100) | 254 |

6. FINANCE COSTS

6. 融資成本

| | | Three months ended 31 March | |
|---|---------------------|--------------------------------|--------------|
| | | 截至三月三十一日止三個月 | |
| | | 2022 | 2021 |
| | | 二零二二年 | 二零二一年 |
| | | RMB'000 | RMB'000 |
| | | 人民幣千元 | 人民幣千元 |
| | | (Unaudited) | (Unaudited) |
| | | (未經審核) | (未經審核) |
| Imputed interests on interest-free deposits from finance lease customers | 融資租賃客戶免息按金的 估算利息 | 48 | 289 |
| Interests on bank and other borrowings | 銀行及其他借款利息 | 2,965 | 1,411 |
| Interests on lease liabilities | 租賃負債利息 | 173 | 341 |
| | | 3,186 | 2,041 |

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

未經審核簡明綜合財務報表附註

7. INCOME TAX EXPENSES

7. 所得稅開支

| | | Three months ended 31 March | |
|-----------------------------|-----------|--------------------------------|-------------|
| | | 截至三月三十一日止三個月 | |
| | | 2022 | 2021 |
| | | 二零二二年 | 二零二一年 |
| | | RMB'000 | RMB'000 |
| | | 人民幣千元 | 人民幣千元 |
| | | (Unaudited) | (Unaudited) |
| | | (未經審核) | (未經審核) |
| The charge comprises: | 支出包括： | | |
| Current tax | 即期稅項 | | |
| – PRC Enterprise Income Tax | – 中國企業所得稅 | 213 | 35 |
| Deferred tax | 遞延稅項 | 24 | 486 |
| | | <u>237</u> | <u>521</u> |

No provision for taxation in Hong Kong has been made as the Group's income neither arises in, nor is derived from, Hong Kong.

Under the Enterprise Income Tax Law of PRC (the "EIT Law") and the Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% for both periods, except for one subsidiary of the Group which is recognised as high technology enterprise is entitled to enjoy a preferential tax rate of 15%.

According to the EIT Law and the Implementation of the EIT Law of the PRC, certain PRC subsidiaries of the Group qualified as small low profit enterprises with annual taxable income not more than RMB1,000,000, and the portion that exceeds RMB1,000,000 but does not exceed RMB3,000,000 (inclusive) are entitled to enterprise income tax calculated at 12.5% and 50% of its taxable income at a tax rate of 20%, respectively.

概無就香港稅項作出撥備，原因為本集團之收入並非於香港產生或來自香港。

除本集團一家被認為高新技術企業之附屬公司有權享有優惠企業所得稅率15%外，根據中國企業所得稅法（「企業所得稅法」）及企業所得稅法實施條例，中國附屬公司於兩個期間之稅率均為25%。

根據中國企業所得稅法及企業所得稅法實施條例，符合小型微利企業條件的若干本集團中國附屬公司不超過人民幣1,000,000元及超過人民幣1,000,000元但不足人民幣3,000,000元（含人民幣3,000,000元）部分的應課稅收入，分別減按12.5%及50%計入應納稅所得額，按20%的稅率繳納企業所得稅。

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

未經審核簡明綜合財務報表附註

8. PROFIT FOR THE PERIOD

Profit for the period is arrived at after charging:

8. 期內溢利

期內溢利已扣除以下各項後達致：

| | | Three months ended 31 March | |
|--|--------------------------|--------------------------------|--------------|
| | | 截至三月三十一日止三個月 | |
| | | 2022 | 2021 |
| | | 二零二二年 | 二零二一年 |
| | | RMB'000 | RMB'000 |
| | | 人民幣千元 | 人民幣千元 |
| | | (Unaudited) | (Unaudited) |
| | | (未經審核) | (未經審核) |
| Directors' emoluments | 董事薪酬 | 726 | 436 |
| Other staff costs | 其他員工成本 | | |
| – Salaries, allowances and other staff benefits | – 薪金、津貼及其他員工福利 | 8,973 | 6,640 |
| – Staffs' retirement benefit scheme contributions | – 員工退休福利計劃供款 | 1,560 | 978 |
| Total staff costs | 員工成本總額 | <u>11,259</u> | <u>8,054</u> |
| Less: staff costs recognised as research and development costs | 減：確認為研發成本的員工成本 | <u>(1,123)</u> | <u>(457)</u> |
| Staff costs recognised in profit or loss | 於損益確認之員工成本 | <u>10,136</u> | <u>7,597</u> |
| Amortisation of intangible assets | 無形資產攤銷 | 255 | 258 |
| Cost of inventories sold | 銷售存貨成本 | 6,611 | – |
| Depreciation of property, plant and equipment | 物業、廠房及設備折舊 | 934 | 1,228 |
| Depreciation of right-of-use assets | 使用權資產折舊 | 2,322 | 2,474 |
| Research and development costs recognised as an expense (included in other operating expenses) | 確認為開支的研發成本 (計入其他營運開支) | 123 | 472 |
| Short-term leases payments | 短期租賃付款 | <u>1,411</u> | <u>1,323</u> |

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 未經審核簡明綜合財務報表附註

9. DIVIDENDS

The board of Directors of the Company does not recommend the payment of an interim dividend in respect of the three months ended 31 March 2022 (three months ended 31 March 2021: Nil).

10. EARNINGS PER SHARE

The calculation of basic earnings per share is based on the profit attributable to owners of the Company of approximately RMB2,155,000 (three months ended 31 March 2021: RMB3,011,000) and on the weighted average number of ordinary shares in issue during the period of 400,000,000 (three months ended 31 March 2021: 400,000,000).

Diluted earnings per share is the same as basic earnings per share as there was no potential dilutive ordinary share in issue during both periods.

9. 股息

本公司董事會並不建議就截至二零二二年三月三十一日止三個月派付中期股息(截至二零二一年三月三十一日止三個月：無)。

10. 每股盈利

每股基本盈利乃根據公司擁有人應佔溢利約人民幣2,155,000元(截至二零二一年三月三十一日止三個月：人民幣3,011,000元)及期內已發行普通股之加權平均數400,000,000股(截至二零二一年三月三十一日止三個月：400,000,000股)計算。

由於兩個期內並無已發行潛在攤薄普通股，故每股攤薄盈利與每股基本盈利相同。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

The Board of Directors of the Company announces the unaudited condensed consolidated quarterly results of the Group for the three months ended 31 March 2022 together with the corresponding comparative figures.

BUSINESS REVIEW

For the three months ended 31 March 2022, the Group is principally engaged in provision of medical equipment finance leasing services, maternal and child postpartum care industry services and trading of medical equipments and consumables business in the PRC.

Finance leasing services

The Group has been focusing on provision of finance leasing services to SMEs customers in the medical equipment industry in various provinces, municipalities, and autonomous regions in the PRC, where the Group has established connections with industry players and gained operational expertise. The finance lease offered by the Group comprises direct finance leasing and sale-leaseback. The Group provided services to approximately 3,390 SMEs customers across 30 provinces, municipalities and autonomous regions in the PRC as at 31 March 2022. The Group derived a revenue of RMB11.8 million from the finance leasing services for the three months ended 31 March 2022.

本公司董事會公佈本集團截至二零二二年三月三十一日止三個月的未經審核簡明綜合季度業績，連同相應比較數字。

業務回顧

本集團在截至二零二二年三月三十一日止三個月主要於中國從事提供醫療器械設備融資租賃服務、母嬰月子產業服務及醫療器械及耗材貿易業務。

融資租賃服務

本集團專注於在中國多個省、市及自治區向醫療器械設備行業的中小企業客戶提供融資租賃服務，本集團在該等地區已與從業者建立聯繫並獲得專業營運知識。本集團提供的融資租賃包括直接融資租賃及售後回租。於二零二二年三月三十一日，本集團向遍佈中國30個省、市及自治區約3,390個中小企業客戶提供服務。截至二零二二年三月三十一日止三個月，本集團融資租賃服務實現收入人民幣11.8百萬元。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

Maternal and child postpartum care industry services

Postpartum confinement (坐月) is a traditional Chinese custom, which allows women to rest fully after giving birth, and to recover through diet. It is said that it is the best time for women to improve their physical well-being. Hence, centres for the provision of postpartum care services (月子中心) had emerged.

The Group provided postpartum care services, consisting of four major areas of (i) health care for postpartum mothers and newborn babies; (ii) dietary and nutrition for postpartum mothers; (iii) recovery and beauty for postpartum mothers; and (iv) intellectual development for newborn babies. The Group derived a revenue of RMB11.9 million from the maternal and child postpartum care industry services for the three months ended 31 March 2022.

Trading of medical equipments and consumables business

The Group is engaged in the trading of medical equipments and consumables in the PRC. The Group derived a revenue of RMB8.1 million from trading of medical equipments and consumables business for the three months ended 31 March 2022.

母嬰月子產業服務

坐月為中國傳統習俗，讓婦女在產後能夠獲得充分休息，並通過飲食復原。據說坐月為婦女提升身體健康之最佳時機，故月子中心因此出現。

本集團提供月子服務，包括四大範疇，即(i)產婦及新生嬰兒的健康護理；(ii)產婦的膳食及營養；(iii)產婦的康復及美容；及(iv)新生嬰兒的智力發展。截至二零二二年三月三十一日止三個月，本集團母嬰月子產業服務實現收入人民幣11.9百萬元。

醫療器械及耗材貿易業務

本集團在中國從事醫療器械及耗材貿易業務。截至二零二二年三月三十一日止三個月，本集團醫療器械及耗材貿易業務實現收入人民幣8.1百萬元。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

OUTLOOK

The Group is still reasonably optimistic to sustain the core business given all the economic uncertainties with the outbreak of Covid-19. The Group will continue to seek for the best possible opportunities to grow the Group's business by leveraging current client base. After the pandemic, the healthcare industry will be a new economic breakthrough with significant value-added potentials. The Group initiated pre-emptive deployment of finance leasing service and medical equipment fields that focus on oral cavity and maternity and child industry. Meanwhile, the Group developed trading of medical equipments and consumables business, which cooperates with the maternal and child postpartum care industry, in order to capture pioneer opportunities and support the industrial upgrade of the healthcare industry, diversifying the income of the Group.

In 2022, the global economic situation remains grim. We will continue to increase investment in various businesses and continue to strive to find opportunities in the face of challenges, so as to return shareholders and the public, and realize corporate value as well as social value.

展望

面對新型冠狀病毒肺炎爆發為經濟帶來不確定性，本集團對維持核心業務仍然樂觀，不斷尋求最佳機會，通過現有的客戶群發展本集團業務。疫情過後，大健康產業將成為極具增值潛力的新經濟突破點。本集團已搶先佈局融資租賃服務專注於口腔及婦幼行業的醫療器械設備領域並開展醫療器械設備及耗材貿易業務，配合母嬰月子產業服務，搶佔風口先機，幫助大健康產業升級，亦使本集團的收入點多元化。

二零二二年，全球經濟形勢依然嚴峻。我們會繼續加大對各業務的投入並持續努力在挑戰中尋找機遇，以回報股東及公眾，實現企業價值及社會價值。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

FINANCIAL REVIEW

Revenue

Revenue consists of (i) finance leasing income and interest income from loan receivables in finance leasing services; (ii) postpartum care services income; and (iii) income from trading of medical equipments and consumables. For the three months ended 31 March 2022, the Group's revenue increased by approximately RMB9.2 million or approximately 40.8% to approximately RMB31.8 million (three months ended 31 March 2021: approximately RMB22.6 million). The increase in revenue for the three months ended 31 March 2022 was mainly attributable to (i) postpartum care services income increased from approximately RMB9.4 million for the three months ended 31 March 2021 to approximately RMB11.9 million for the three months ended 31 March 2022; and (ii) income from trading of medical equipments and consumables of approximately RMB8.1 million (three months ended 31 March 2021: Nil), which offsetting the finance leasing income decreased from approximately RMB13.2 million for the three months ended 31 March 2021 to approximately RMB11.8 million for the three months ended 31 March 2022.

Cost of sales

Cost of sales represents the cost of medical equipments and consumables sold during the period.

Staff cost

Staff costs include primarily Directors' remuneration, employee salaries, allowances and other staff benefits as well as employee retirement benefits scheme contributions. Staff costs increased from RMB7.6 million for the three months ended 31 March 2021 to approximately RMB10.1 million for the three months ended 31 March 2022. The increase was mainly attributable to (i) the increase in head count and staff salaries for existing staff; and (ii) the staff costs incurred by postpartum care services business increased from approximately RMB3.0 million for the three months ended 31 March 2021 to approximately RMB4.4 million for the three months ended 31 March 2022.

財務回顧

收益

收入包括(i)融資租賃服務之融資租賃收入和應收貸款利息收入；(ii)月子服務收入；及(iii)醫療器械及耗材貿易收入。截至二零二二年三月三十一日止三個月，本集團的收益增加約人民幣9.2百萬元或約40.8%至約人民幣31.8百萬元(截至二零二一年三月三十一日止三個月：約人民幣22.6百萬元)。截至二零二二年三月三十一日止三個月收益增加主要歸因於(i)月子服務收入由截至二零二一年三月三十一日止三個月的約人民幣9.4百萬元增加至二零二二年三月三十一日止三個月的約人民幣11.9百萬元；及(ii)醫療器械及耗材貿易收入約為人民幣8.1百萬元(截至二零二一年三月三十一日止三個月：零)，其抵銷融資租賃收入由二零二一年三月三十一日止三個月的約人民幣13.2百萬元減至二零二二年三月三十一日止三個月的約人民幣11.8百萬元。

銷售成本

銷售成本代表期內醫療器械及耗材業務的銷售成本。

員工成本

員工成本主要包括董事薪酬、僱員薪資、津貼及其他員工福利，以及僱員退休福利計劃供款。員工成本由截至二零二一年三月三十一日止三個月的人民幣7.6百萬元增至截至二零二二年三月三十一日止三個月的約人民幣10.1百萬元。有關增加主要是由於(i)員工人數及現有員工的員工薪金增加；及(ii)月子服務業務所產生之員工成本，由截至二零二一年三月三十一日止三個月的約人民幣3.0百萬元增加至截至二零二二年三月三十一日止三個月的約人民幣4.4百萬元。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

(Reversal of impairment losses)/impairment losses under expected credit loss (“ECL”) model, net

The Group is not required to provide general provisions as commercial banks and other financial institutions which the China Banking Regulatory Commission regulates. The provisioning policies are based on the applicable accounting standards. The management assesses the measurement of ECL in relation to finance lease receivables and loan receivables. In determining the impairment of finance lease receivables and loan receivables, the management considers shared credit risk characteristics including industry types, historical past due information and lessees' creditworthiness for grouping, and assesses credit losses based on internal credit rating and on a forward looking basis with the use of appropriate models and assumptions relate to the economic inputs and the future macroeconomic conditions in accordance with Hong Kong Financial Reporting Standard 9.

For the three months ended 31 March 2022, reversal of impairment loss of approximately RMB1.1 million (three months ended 31 March 2021: impairment loss of RMB0.3 million) was recognised. The reversal of impairment losses recognised in current period was mainly due to the decrease in total finance lease receivables.

Other operating expenses

Other operating expenses include primarily travelling expenses, depreciation of property, plant and equipment, depreciation of right-of-use assets, short-term leases payments and the operating expenses incurred by maternal and child postpartum care business. Other operating expenses increased from approximately RMB10.5 million for the three months ended 31 March 2021 to approximately RMB12.0 million for the three months ended 31 March 2022. The increase was mainly due to the increase in other operating expenses of the postpartum care business offsetting the decrease in other operating expenses of the finance leasing business.

預期信用損失（「預期信用損失」）模式項下之減值虧損撥回／（減值虧損）淨額

本集團毋須如中國銀行業監督管理委員會所監管的商業銀行及其他金融機構般提供一般準備金。有關準備金政策乃根據適用會計標準。管理層評估有關融資租賃應收款項及應收貸款之預期信用損失之計量。根據香港財務報告準則第9號，於釐定融資租賃應收款項及應收貸款減值時，管理層就分組考慮共享信用風險特徵，包括行業類別、過往逾期資料及承租人信譽，並按內部信貸評級及前瞻性基礎並使用適當模型及有關經濟輸入數據及未來宏觀經濟環境之假設評估信貸虧損。

截至二零二二年三月三十一日止三個月，已確認減值虧損撥回約人民幣1.1百萬元（截至二零二一年三月三十一日止三個月：減值虧損人民幣0.3百萬元）。本期確認的減值虧損撥回主要是融資租賃應收款項總額減少所致。

其他經營開支

其他經營開支主要包括差旅開支、物業、廠房及設備折舊、使用權資產折舊、短期租賃付款及母嬰月子業務所產生之經營開支。其他經營開支由截至二零二一年三月三十一日止三個月的約人民幣10.5百萬元增至由截至二零二二年三月三十一日止三個月的約人民幣12.0百萬元。有關增加主要由於月子會所業務的其他經營開支增加抵銷了融資租賃業務的其他經營開支減少。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

The other operating expenses for the postpartum care business increased from approximately RMB5.8 million for the three months ended 31 March 2021 to approximately RMB8.5 million for the three months ended 31 March 2022, it was mainly attributable to (i) the miscellaneous expenses of postpartum care business increased from approximately RMB2.3 million for the three months ended 31 March 2021 to approximately RMB3.2 million for the three months ended 31 March 2022; (ii) depreciation of right-of-use assets increased from approximately RMB1.5 million for the three months ended 31 March 2021 to approximately RMB2.0 million for the three months ended 31 March 2022; (iii) short-term leases payments increased from approximately RMB0.9 million for the three months ended 31 March 2021 to approximately RMB1.4 million for the three months ended 31 March 2022; and (iv) office expenses, water, electricity and property management fees increased from approximately RMB0.4 million for the three months ended 31 March 2021 to approximately RMB0.8 million for the three months ended 31 March 2022.

The other operating expenses for finance leasing business decreased from approximately RMB4.7 million for the three months ended 31 March 2021 to approximately RMB3.5 million for the three months ended 31 March 2022. The decrease was mainly attributed to (i) depreciation of property, plant and equipment decreased from approximately RMB0.9 million for the three months ended 31 March 2021 to approximately RMB0.3 million for the three months ended 31 March 2022; and (ii) due to the impact of Covid-19, travelling expenses decreased from approximately RMB1.0 million for the three months ended 31 March 2021 to approximately RMB0.4 million for the three months ended 31 March 2022.

月子會所業務的其他經營開支由截至二零二一年三月三十一日止三個月的約人民幣5.8百萬元增至由截至二零二二年三月三十一日止三個月的約人民幣8.5百萬元，主要是由於(i)產後護理服務業務的雜項費用由截至二零二一年三月三十一日止三個月的約人民幣2.3百萬元增至由截至二零二二年三月三十一日止三個月的約人民幣3.2百萬元；(ii)使用權資產折舊由截至二零二一年三月三十一日止三個月的約人民幣1.5百萬元增至由截至二零二二年三月三十一日止三個月的約人民幣2.0百萬元；(iii)短期租賃付款由截至二零二一年三月三十一日止三個月的約人民幣0.9百萬元增至由截至二零二二年三月三十一日止三個月的約人民幣1.4百萬元；及(iv)辦公費、水電及物業管理費由截至二零二一年三月三十一日止三個月的約人民幣0.4百萬元增至由截至二零二二年三月三十一日止三個月的約人民幣0.8百萬元。

融資租賃業務的其他經營開支由截至二零二一年三月三十一日止三個月的約人民幣4.7百萬元縮減至由截至二零二二年三月三十一日止三個月的約人民幣3.5百萬元。截至二零二二年三月三十一日止三個月其他經營開支縮減主要歸因於(i)使用權資產折舊的折舊由截至二零二一年三月三十一日止三個月的約人民幣0.9百萬元縮減截至二零二二年三月三十一日止三個月的約人民幣0.3百萬元；及(ii)由於Covid-19疫情的影響，差旅開支由截至二零二一年三月三十一日止三個月的約人民幣1.0百萬元縮減截至二零二二年三月三十一日止三個月的約人民幣0.4百萬元。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

Finance costs

Finance costs consist of (i) imputed interest expense on interest-free deposits from finance lease customers; (ii) interest on bank and other borrowings; and (iii) interests on lease liabilities. Finance costs increased from approximately RMB2.0 million for the three months ended 31 March 2021 to approximately RMB3.2 million for the three months ended 31 March 2022. The increase was mainly due to the interest on bank borrowing increased from approximately RMB1.4 million for the three months ended 31 March 2021 to approximately RMB3.0 million for the three months ended 31 March 2022.

Income tax expenses

Certain PRC subsidiaries of the Group qualified as small low-profit enterprises with annual taxable income not more than RMB1.0 million, and the portion that exceeds RMB1.0 million but does not exceed RMB3.0 million (inclusive) are entitled to enterprise income tax calculated at 12.5% and 50% of its taxable income at a tax rate of 20%, respectively. A PRC subsidiary of the Group recognised as high technology enterprise is entitled to a preferential enterprise income tax rate of 15%. The enterprise income tax rate applicable to the other PRC subsidiaries of the Group is 25%.

融資成本

融資成本包括(i)來自融資租賃客戶的免息按金的估算利息開支；(ii)銀行及其他借款利息；及(iii)租賃負債利息。融資成本由截至二零二一年三月三十一日止三個月的約人民幣2.0百萬元增加至截至二零二二年三月三十一日止三個月的約人民幣3.2百萬元。增加的主要因為來自銀行借款利息由截至二零二一年三月三十一日止三個月的約人民幣1.4百萬元增至截至二零二二年三月三十一日止三個月的約人民幣3.0百萬元。

所得稅開支

本集團若干附屬公司符合小型微利企業條件的不超過人民幣1.0百萬元及超過人民幣1.0百萬元但不足人民幣3.0百萬元(含人民幣3.0百萬元)部分的應課稅收入，分別減按12.5%及50%計入應納稅所得額，按20%的稅率繳納企業所得稅。本集團一家被認定為高新技術企業之中國附屬公司有權享有優惠企業所得稅率15%。適用於本集團其他中國附屬公司的企業所得稅稅率為25%。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

Profit and total comprehensive income attributable to owners of the Company

For the three months ended 31 March 2022 and 2021, the Group's profit and total comprehensive income attributable to owners of the Company was approximately RMB2.2 million and RMB3.0 million, respectively. The decrease of profit and total comprehensive income attributable to owners of the Company for the three months ended 31 March 2022 was mainly attributable to the increase in staff costs, other operating expenses and finance costs which offsetting the increase in revenue and reversal of impairment losses under ECL model, net as compared to the corresponding period in 2021.

Dividend

The Board of Directors of the Company does not recommend the payment of an interim dividend in respect of the three months ended 31 March 2022 (three months ended 31 March 2021: Nil).

CAPITAL STRUCTURE

The shares of the Company (the "Shares") were successfully listed on the GEM of the Stock Exchange on 9 July 2018. There has been no change in the capital structure of the Group since then. The share capital of the Group only comprises ordinary Shares.

As at 31 March 2022, the Company's issued share capital was HK\$40,000,000 and the number of its issued ordinary Shares was 400,000,000 of HK\$0.1 each.

本公司擁有人應佔溢利及全面收入總額

截至二零二二年及二零二一年三月三十一日止三個月，本集團的本公司擁有人應佔溢利及全面收入總額分別為約人民幣2.2百萬元及人民幣3.0百萬元。截至二零二二年三月三十一日止三個月，本公司擁有人應佔溢利及全面收入總額減少，主要是由於較二零二一年同期員工成本、其他經營開支及融資成本增加，其抵銷收益及預期信用損失模式項下之減值虧損撥回淨額增加所致。

股息

本公司董事會並不建議就截至二零二二年三月三十一日止三個月派付中期股息（截至二零二一年三月三十一日止三個月：無）。

資本架構

本公司股份（「股份」）於二零一八年七月九日在聯交所GEM成功上市。自此，本集團的資本架構並無變動。本集團的股本僅包括普通股。

於二零二二年三月三十一日，本公司的已發行股本為40,000,000港元，而其已發行普通股數目為400,000,000股，每股面值為0.1港元。

DISCLOSURE OF INTEREST

Directors' and chief executive's interests and short positions in Shares and underlying Shares and debentures of the Company and its associated corporations

As at 31 March 2022, the interests and short positions of the Directors and the chief executive of the Company in the Shares, underlying Shares and debentures of the Company and any of its associated corporations (within the meaning of Part XV of SFO) which are required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of part XV of the SFO (including interests and short positions in which they are taken or deemed to have under such provisions of the SFO); or (b) pursuant to section 352 of the SFO, to be entered in the register referred to therein; or (c) have to be notified to the Company and the Stock Exchange pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules, were as follows:

Long positions in the Shares

| Name of Director/ chief executive | Capacity/ Nature of interest | Number of Shares held/interested in 持有／擁有 權益的股份數目 | Approximate percentage of shareholding ⁽¹⁾ 股權概約百分比 ⁽¹⁾ |
|--|---|--|---|
| 董事／主要行政人員姓名 | 身份／權益性質 | | |
| Mr. Zhang Junshen ^{(1) (2)} 張俊深先生 ^{(1) (2)} | Interest in controlled corporation; interest held jointly with another person 受控制法團權益；與另一名人士共同持有的權益 | 300,000,000 | 75% |
| Mr. Zhang Junwei ^{(1) (3)} 張俊偉先生 ^{(1) (3)} | Interest in controlled corporation; interest held jointly with another person 受控制法團權益；與另一名人士共同持有的權益 | 300,000,000 | 75% |

權益披露

董事及主要行政人員於本公司及其相聯法團的股份、相關股份及債權證的權益及淡倉

於二零二二年三月三十一日，本公司董事及主要行政人員於本公司及其任何相聯法團（定義見證券及期貨條例第XV部）的股份、相關股份及債權證中擁有：(a)根據證券及期貨條例第XV部第7及第8分部須知會本公司及聯交所（包括彼等根據證券及期貨條例之該等條文被當作或視為擁有的權益及淡倉）；或(b)根據證券及期貨條例第352條須記錄於該條所述登記冊；或(c)根據GEM上市規則第5.46至5.67條須知會本公司及聯交所的權益及淡倉如下：

於股份的好倉

OTHER INFORMATION 其他資料

Notes:

- (1) On 24 February 2017, the ultimate controlling shareholders of the Company, namely Mr. Zhang Junshen and Mr. Zhang Junwei entered into a concert parties confirmatory deed to acknowledge and confirm, among other things, that they are parties acting in concert with each member of the Group from the incorporation dates of the respective members of the Group and continue as at and after the date of the concert parties confirmatory deed, details of which are set out in the subsection headed “History and Reorganisation – Parties Acting in Concert” in the Company’s prospectus dated 25 June 2018 (the “**Prospectus**”). As such, pursuant to the parties acting in concert arrangement, each of the controlling shareholders of the Company, namely Hero Global Limited (“**Hero Global**”) (being wholly owned by Mr. Zhang Junshen), Mr. Zhang Junshen, Icon Global Holding Limited (“**Icon Global**”) (being wholly owned by Mr. Zhang Junwei) and Mr. Zhang Junwei, is deemed to be interested in 75.0% of the issued share capital of the Company.
- (2) 300,000,000 Shares in which Mr. Zhang Junshen is interested consist of the following: (i) 219,801,980 Shares held by Hero Global, a company wholly owned by Mr. Zhang Junshen, in which Mr. Zhang Junshen is deemed to be interested under the SFO; and (ii) 80,198,020 Shares in which Mr. Zhang Junshen is deemed to be interested as a result of being a party acting-in-concert with Mr. Zhang Junwei.
- (3) 300,000,000 Shares in which Mr. Zhang Junwei is interested consist of (i) 80,198,020 Shares held by Icon Global, a company wholly owned by Mr. Zhang Junwei, in which Mr. Zhang Junwei is deemed to be interested under the SFO; and (ii) 219,801,980 Shares in which Mr. Zhang Junwei is deemed to be interested as a result of being a party acting-in-concert with Mr. Zhang Junshen.

附註：

- (1) 於二零一七年二月二十四日，本公司的最終控股股東，即張俊深先生及張俊偉先生訂立一致行動人士確認契據，承認及確認（其中包括）自本集團各成員公司註冊成立日期起及直至一致行動人士確認契據日期及其後，彼等為本集團各成員公司的一致行動人士。有關一致行動人士確認契據的詳情載於本公司日期為二零一八年六月二十五日之招股章程（「**招股章程**」）章程「歷史及重組——一致行動人士」分節。因此，根據一致行動人士安排，本公司各控股股東，即Hero Global Limited（「**Hero Global**」）（由張俊深先生全資擁有）、張俊深先生、標緻全球控股有限公司（「**標緻全球**」）（由張俊偉先生全資擁有）及張俊偉先生，被視為於本公司75.0%已發行股本擁有權益。
- (2) 張俊深先生擁有權益的300,000,000股股份包括以下各項：(i)由Hero Global（張俊深先生全資擁有的公司）持有的219,801,980股股份，根據證券及期貨條例，張俊深先生被視為於該等股份擁有權益；及(ii)張俊深先生因身為與張俊偉先生一致行動的人士而被視為擁有權益的80,198,020股股份。
- (3) 張俊偉先生擁有權益的300,000,000股股份包括(i)由標緻全球（張俊偉先生全資擁有的公司）持有的80,198,020股股份，根據證券及期貨條例，張俊偉先生被視為於該等股份擁有權益；及(ii)張俊偉先生因身為與張俊深先生一致行動的人士而被視為擁有權益的219,801,980股股份。

OTHER INFORMATION 其他資料

Long position in the associated corporations

於相聯法團的好倉

| Name of Director/ chief executive 董事／主要行政人員姓名 | Name of associated corporations 相聯法團名稱 | Capacity/ nature of interest 身份／權益性質 | Number and class of securities 證券數目及類別 | Percentage of Shareholding 股權百分比 |
|---|--|--|--|--|
| Mr. Zhang Junshen 張俊深先生 | Hero Global | Beneficial owner 實益擁有人 | 50,000 ordinary shares 50,000股普通股 | 100% |
| Mr. Zhang Junwei 張俊偉先生 | Icon Global 標緻全球 | Beneficial owner 實益擁有人 | 100 ordinary shares 100股普通股 | 100% |

Save as disclosed above, as at 31 March 2022, none of the Directors or chief executive of the Company had an interest or short position in any shares or underlying shares and/or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which would have to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions in which they are taken or deemed to have under such provisions of the SFO) or that was required to be recorded in the register kept by the Company pursuant to section 352 of the SFO, or which are required to be notified to the Company and the Stock Exchange, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules.

除上文披露者外，於二零二二年三月三十一日，概無本公司董事或主要行政人員於本公司或其任何相聯法團（定義見證券及期貨條例第XV部）的任何股份或相關股份及／或債權證中擁有根據證券及期貨條例第XV部第7及第8分部須知會本公司及聯交所（包括彼等根據證券及期貨條例之該等條文被當作或視為擁有的權益或淡倉）或根據證券及期貨條例第352條須記錄於本公司存置的登記冊，或根據GEM上市規則第5.46至5.67條須知會本公司及聯交所的權益或淡倉。

OTHER INFORMATION 其他資料

Substantial shareholders' interests and short positions in Shares and underlying Shares of the Company

So far as the Directors are aware, as at 31 March 2022, the persons (other than Directors or chief executive of the Company) who had interests in the Shares and underlying Shares of the Company within the meaning of Part XV of the SFO which are required to be disclosed pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or which will be required, pursuant to Section 336 of the SFO, to be entered in the register of the Company were as follows:

Long positions in the Shares

主要股東於本公司股份及相關股份的權益及淡倉

據董事所知，於二零二二年三月三十一日，於本公司股份及相關股份中擁有權益（定義見證券及期貨條例第XV部），而根據證券及期貨條例第XV部第2及第3分部的條文須予披露或根據證券及期貨條例第336條將須記錄於本公司的登記冊之人士（本公司董事或主要行政人員除外）如下：

於股份的好倉

| Name of shareholder | Capacity/Nature of interest | Number of Shares held/interested in | Approximate percentage of shareholding |
|--|---|-------------------------------------|--|
| 股東名稱／姓名 | 身份／權益性質 | 持有／擁有權益的股份數目 | 股權概約百分比 |
| Hero Global ⁽¹⁾ | Beneficial owner; interests held jointly with another person 實益擁有人；與另一名人士共同持有的權益 | 300,000,000 | 75% |
| Icon Global ⁽¹⁾ 標緻全球 ⁽¹⁾ | Beneficial owner; interests held jointly with another person 實益擁有人；與另一名人士共同持有的權益 | 300,000,000 | 75% |
| Ms. Tang Yiping ⁽²⁾ 湯怡萍女士 ⁽²⁾ | Interest of spouse 配偶權益 | 300,000,000 | 75% |

OTHER INFORMATION 其他資料

Notes:

- (1) On 24 February 2017, the ultimate controlling shareholders of the Company, namely Mr. Zhang Junshen and Mr. Zhang Junwei entered into a concert parties confirmatory deed to acknowledge and confirm, among other things, that they are parties acting in concert with each member of the Group from the incorporation dates of the respective members of the Group and continue as at and after the date of the concert parties confirmatory deed, details of which are set out in the subsection headed “History and Reorganisation – Parties Acting in Concert” in the Prospectus. As such, pursuant to the parties acting in concert arrangement, each of the controlling shareholders of the Company, namely Hero Global (being wholly owned by Mr. Zhang Junshen), Mr. Zhang Junshen, Icon Global (being wholly owned by Mr. Zhang Junwei) and Mr. Zhang Junwei, is deemed to be interested in 75.0% of the issued share capital of the Company.
- (2) Ms. Tang Yiping is the spouse of Mr. Zhang Junshen, and she is deemed, or taken to be, interested in all Shares in which Mr. Zhang Junshen is interested in for the purposes of the SFO.

Save as disclosed above, as at 31 March 2022, the Directors were not aware of any other person (other than the Directors or chief executive of the Company as disclosed in the section headed “Directors’ and chief executive’s interests and short positions in Shares and underlying Shares and debentures of the Company and its associated corporations” above) who had or deemed to have interests or short positions in the shares, underlying shares or debentures of the Company which has to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO and as recorded in the register required to be kept under section 336 of the SFO.

COMPETING INTEREST

For the three months ended 31 March 2022, none of the Directors or the controlling shareholders of the Company or their respective close associates (as defined in the GEM Listing Rules) is interested in any business which competes or is likely to compete, either directly or indirectly, with the business of the Group or has any conflicts of interest with the Group.

附註：

- (1) 於二零一七年二月二十四日，本公司的最終控股股東，即張俊深先生及張俊偉先生訂立一致行動人士確認契據，承認及確認（其中包括）自本集團各成員公司註冊成立日期起及直至一致行動人士確認契據日期及其後，彼等為本集團各成員公司的一致行動人士。有關一致行動人士確認契據的詳情載於招股章程「歷史及重組—一致行動人士」分節。因此，根據一致行動人士安排，本公司各控股股東，即Hero Global（由張俊深先生全資擁有）、張俊深先生、標緻全球（由張俊偉先生全資擁有）及張俊偉先生，被視為於本公司75.0%已發行股本擁有權益。
- (2) 湯怡萍女士為張俊深先生的配偶，因此就證券及期貨條例而言，彼被視為或當作為於張俊深先生擁有權益的所有股份擁有權益。

除上文披露者外，於二零二二年三月三十一日，董事並未察覺到有任何其他人士（上文「董事及主要行政人員於本公司及其相聯法團的股份、相關股份及債權證的權益及淡倉」一節所披露之本公司董事或主要行政人員除外）於本公司股份、相關股份或債權證中擁有或被視作擁有權益或淡倉，而根據證券及期貨條例第XV部第2及第3分部的條文須向本公司披露，及記錄於根據證券及期貨條例第336條須存置的登記冊。

競爭權益

於截至二零二二年三月三十一日止三個月，概無董事或本公司控股股東或彼等各自的緊密聯繫人（定義見GEM上市規則）於直接或間接與本集團業務競爭或可能構成競爭的任何業務中擁有權益，或與本集團有任何利益衝突。

OTHER INFORMATION 其他資料

DEED OF NON-COMPETITION

The controlling shareholders of the Company, namely Mr. Zhang Junshen (through Hero Global), Mr. Zhang Junwei (through Icon Global), (the “**Controlling Shareholders**”) entered into a deed of non-competition dated 12 June 2018 (“**Deed of Non-competition**”) in favour of the Company (for itself and as trustee for each of its subsidiaries). For details of the Deed of Non-competition, please refer to the section headed “Relationship with Controlling Shareholders – Non-competition Undertaking” in the Prospectus. Each of the Controlling Shareholders has confirmed that none of them is engaged in, or interested in any business (other than the Group) which, directly or indirectly, competes or may compete with the business of the Group.

The independent non-executive Directors have also reviewed the status of compliance and confirmed that all the undertakings under the Deed of Non-competition have been complied with by each of the Controlling Shareholders during the period and up to the date of this report.

PURCHASE, SALES OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company’s listed securities during the period and up to the date of this report.

CORPORATE GOVERNANCE PRACTICES

The Company considers the maintenance of a high standard of corporate governance important to the continuous growth of the Group. The Company’s corporate governance practices are based on code provisions as set out in the Corporate Governance Code (the “**CG Code**”) as contained in Appendix 15 of the GEM Listing Rules. Other than the deviation from code provision A.2.1, the Company has adopted and complied with, where applicable, the CG Code to ensure that the Group’s business activities and decision-making processes are regulated in a proper and prudent manner.

Up to the date of this report, other than the deviation from code provision A.2.1, the Company complied with the provisions of the CG Code as set out in Appendix 15 to the GEM Listing Rules.

不競爭契據

本公司控股股東張俊深先生(透過Hero Global)及張俊偉先生(透過標緻全球) (「**控股股東**」)以本公司(為其本身及作為其各附屬公司的受託人)為受益人訂立日期為二零一八年六月十二日的不競爭契據(「**不競爭契據**」)。有關不競爭契據的詳情,請參閱招股章程「與控股股東的關係—不競爭承諾」一節。各控股股東已確認彼等概無從事直接或間接與本集團業務構成或可能構成競爭的任何業務(本集團業務除外),亦無於有關業務中擁有權益。

獨立非執行董事亦已審閱遵守情況,並確認在期內及直至本報告日期,各控股股東已遵守不競爭契據項下的所有承諾。

購買、出售或贖回本公司上市證券

在期內及直至本報告日期,本公司或其任何附屬公司並無購買、出售或贖回本公司任何上市證券。

企業管治常規

本公司認為,維持高水準的企業管治標準對本集團的持續增長至關重要。本公司的企業管治常規根據GEM上市規則附錄十五載列的企業管治守則(「**企業管治守則**」)所載的守則條文作出。除偏離守則條文A.2.1外,本公司已採納及遵守(如適用)企業管治守則以確保本集團的業務活動及決策程序得到妥善及審慎規管。

直至本報告日期,除偏離守則條文A.2.1外,本公司一直遵守GEM上市規則附錄十五載列的企業管治守則的條文。

CODE PROVISION A.2.1

In accordance with the code provision A.2.1 of the CG Code, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. The Board is of the view that although Mr. Zhang Junshen is the chairman and the chief executive officer of the Company, this structure will not impair the balance of power and authority between the Board and the management of the Company. The balance of power and authority is ensured by the operations of the Board, which comprises experienced and high caliber individuals and meets regularly to discuss issues affecting operations of the Company. The Board believes that this structure is conducive to strong and consistent leadership, enabling the Group to make and implement decisions promptly and efficiently. The Board has full confidence in Mr. Zhang Junshen and believes that his appointment to the posts of chairman and chief executive officer is beneficial to the business prospects of the Company.

EVENT AFTER THE REPORTING PERIOD

The Directors are not aware of any significant event which had material effect on the Group subsequent to 31 March 2022 and up to the date of this report.

SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted Rules 5.48 to 5.67 of the GEM Listing Rules as its own code of conduct (“**Code of Conduct**”) regarding securities transactions by the Directors. The Company has confirmed, having made specific enquiry of the Directors, that all the Directors have complied with the Code of Conduct for the three months ended 31 March 2022 and up to date of this report.

守則條文A.2.1

按照企業管治守則守則條文A.2.1，主席與行政總裁的角色應有區分，並不應由一人同時兼任。董事會認為，儘管張俊深先生為本公司主席及行政總裁，該架構並不會損害董事會與本公司管理層之間的權力及權限平衡。因為董事會由經驗豐富的高素質個人組成且定期開會討論影響本公司經營的問題，這種運作確保了權力及權限平衡。董事會相信，該架構有助於樹立強勢及一致的領導作風，令本集團能夠迅速高效地作出並執行決策。董事會充分信任張俊深先生，認為委任其為主席及行政總裁有利於本公司的業務前景。

報告期後事項

董事並不知悉於二零二二年三月三十一日後及直至本報告日期期間存在對本集團造成重大影響的任何重大事項。

董事進行證券交易

本公司已採納GEM上市規則第5.48條至第5.67條作為其本身有關董事進行證券交易之操守準則（「**操守準則**」）。經向董事作出特定查詢後，本公司已確認全體董事已於截至二零二二年三月三十一日止三個月及直至本報告日期遵守操守準則。

OTHER INFORMATION 其他資料

AUDIT COMMITTEE AND REVIEW OF QUARTERLY RESULTS

The Group has established an audit committee (the “**Audit Committee**”) pursuant to a resolution of the Directors passed on 12 June 2018 in compliance with Rules 5.28 to 5.33 of the GEM Listing Rules and with written terms of reference in compliance with the CG Code.

The Audit Committee currently consists of our non-executive Director, namely Mr. Lyu Di and two of our independent non-executive Directors, namely Mr. Chan Chi Fung Leo and Dr. Deng Bin. Mr. Chan Chi Fung Leo currently serves as the chairman of the Audit Committee, who holds the appropriate professional qualifications as required under Rules 5.05(2) and 5.28 of the GEM Listing Rules.

The financial information in this report has not been audited. The Audit Committee has reviewed the unaudited condensed consolidated financial statements of the Group for the three months ended 31 March 2022 and is of the opinion that the preparation of such statements complied with the applicable accounting standards, the requirements under the GEM Listing Rules and other applicable legal requirements, and that adequate disclosures had been made.

By order of the Board
Ziyuanyuan Holdings Group Limited
Zhang Junshen
Chairman and Chief Executive Officer

Hong Kong, 13 May 2022

As at the date of this report, the executive Directors are Mr. Zhang Junshen (Chairman and Chief Executive Officer) and Mr. Zhang Yong, the non-executive Director is Mr. Lyu Di, and the independent non-executive Directors are Mr. Chan Chi Fung Leo, Mr. Chow Siu Hang and Dr. Deng Bin.

審核委員會及季度業績審閱

本集團已遵照GEM上市規則第5.28條至第5.33條根據於二零一八年六月十二日通過的董事決議案成立審核委員會（「**審核委員會**」），並按企業管治守則制定書面職權範圍。

審核委員會現時由非執行董事呂迪先生及其中兩名獨立非執行董事陳志峰先生及鄧斌博士組成。陳志峰先生目前擔任審核委員會主席，彼持有GEM上市規則第5.05(2)及5.28條規定之適當專業資格。

本報告之財務資料未經審核。審核委員會已審閱本集團截至二零二二年三月三十一日止三個月的未經審核簡明綜合財務報表，並認為有關報表已遵循適用會計準則、GEM上市規則項下的規定及其他適用法律規定編製，並已作出充分披露。

承董事會命
紫元元控股集團有限公司
主席及行政總裁
張俊深

香港，二零二二年五月十三日

於本報告日期，執行董事為張俊深先生（主席及行政總裁）及張勇先生，非執行董事為呂迪先生，而獨立非執行董事為陳志峰先生、周兆恒先生及鄧斌博士。



紫元元
ZIYUANYUAN